Published in Virology on January 01, 1988
Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol (1997) 2.51
Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus. Proc Natl Acad Sci U S A (1989) 1.71
Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus. J Virol (1989) 1.59
Evidence for positive selection in foot-and-mouth disease virus capsid genes from field isolates. Genetics (2001) 1.49
Mutations located on both F1 and F2 subunits of the Newcastle disease virus fusion protein confer resistance to neutralization with monoclonal antibodies. J Virol (1989) 1.30
Antigenic heterogeneity of a foot-and-mouth disease virus serotype in the field is mediated by very limited sequence variation at several antigenic sites. J Virol (1994) 1.23
Foot-and-mouth disease virus receptors: comparison of bovine alpha(V) integrin utilization by type A and O viruses. J Virol (2003) 1.11
Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants. J Virol (1991) 1.07
Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J Virol (1991) 1.04
Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV. J Virol (1994) 1.02
High-efficiency utilization of the bovine integrin alpha(v)beta(3) as a receptor for foot-and-mouth disease virus is dependent on the bovine beta(3) subunit. J Virol (2000) 0.98
Characterizing sequence variation in the VP1 capsid proteins of foot and mouth disease virus (serotype 0) with respect to virion structure. J Mol Evol (1998) 0.90
Evaluation of a genetically modified foot-and-mouth disease virus vaccine candidate generated by reverse genetics. BMC Vet Res (2012) 0.87
Identification of cellular genes affecting the infectivity of foot-and-mouth disease virus. J Virol (2009) 0.84
Xenoepitope substitution avoids deceptive imprinting and broadens the immune response to foot-and-mouth disease virus. Clin Vaccine Immunol (2012) 0.75
A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature (2000) 10.16
Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose. Cell (1986) 8.87
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol (1995) 7.57
Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science (1992) 6.40
Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine. Science (1981) 5.66
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature (1993) 5.31
Crystal structure of cyclin-dependent kinase 2. Nature (1993) 5.21
Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J (1992) 4.21
Inhibitory phosphorylation of the APC regulator Hct1 is controlled by the kinase Cdc28 and the phosphatase Cdc14. Curr Biol (1999) 3.96
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (1998) 3.53
Insulin-like growth factor II receptor as a multifunctional binding protein. Nature (1987) 3.52
Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci U S A (1992) 3.38
A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell (1994) 3.35
Leader protein of foot-and-mouth disease virus is required for cleavage of the p220 component of the cap-binding protein complex. J Virol (1988) 3.28
A late mitotic regulatory network controlling cyclin destruction in Saccharomyces cerevisiae. Mol Biol Cell (1998) 3.18
Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature (1995) 3.05
The Polo-related kinase Cdc5 activates and is destroyed by the mitotic cyclin destruction machinery in S. cerevisiae. Curr Biol (1998) 2.92
c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev (1995) 2.72
Activation of human cyclin-dependent kinases in vitro. Mol Biol Cell (1992) 2.68
The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev (1997) 2.38
Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol (2000) 2.36
Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol (1999) 2.35
Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol (1998) 2.33
Association of p60c-src with endosomal membranes in mammalian fibroblasts. J Cell Biol (1992) 2.30
PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A (1994) 2.29
Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol (1996) 2.21
Pds1 and Esp1 control both anaphase and mitotic exit in normal cells and after DNA damage. Genes Dev (1999) 2.14
Association of the amino-terminal half of c-Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527. EMBO J (1994) 2.08
Cell cycle control by a complex of the cyclin HCS26 (PCL1) and the kinase PHO85. Science (1994) 1.94
Immunochemical studies of foot-and-mouth disease. VII. Characterization of foot-and-mouth disease virus concentrated by polyethylene glycol precipitation. Arch Gesamte Virusforsch (1970) 1.93
Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase. Cell (1995) 1.92
Insulin action is blocked by a monoclonal antibody that inhibits the insulin receptor kinase. Proc Natl Acad Sci U S A (1986) 1.80
Proteolytic processing of foot-and-mouth disease virus polyproteins expressed in a cell-free system from clone-derived transcripts. J Virol (1987) 1.77
Epitopes on foot-and-mouth disease virus outer capsid protein VP1 involved in neutralization and cell attachment. J Virol (1984) 1.75
Acute insulin action requires insulin receptor kinase activity: introduction of an inhibitory monoclonal antibody into mammalian cells blocks the rapid effects of insulin. Proc Natl Acad Sci U S A (1987) 1.73
Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol Cell Biol (1994) 1.71
A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Science (1996) 1.68
Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J (1994) 1.67
Cdc37 is required for association of the protein kinase Cdc28 with G1 and mitotic cyclins. Proc Natl Acad Sci U S A (1995) 1.62
Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus. J Virol (1989) 1.59
Cdc14 activates cdc15 to promote mitotic exit in budding yeast. Curr Biol (2000) 1.58
Kaposi's sarcoma-associated herpesvirus K-bZIP protein is phosphorylated by cyclin-dependent kinases. J Virol (2001) 1.51
Identification of amino acid and nucleotide sequence of the foot-and-mouth disease virus RNA polymerase. Virology (1983) 1.51
Biochemical map of polypeptides specified by foot-and-mouth disease virus. J Virol (1984) 1.46
Suppression of c-Src activity by C-terminal Src kinase involves the c-Src SH2 and SH3 domains: analysis with Saccharomyces cerevisiae. Mol Cell Biol (1993) 1.44
Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. Mol Cell Biol (1995) 1.44
Cak1 is required for Kin28 phosphorylation and activation in vivo. Mol Cell Biol (1998) 1.39
Ran-independent nuclear import of cyclin B1-Cdc2 by importin beta. Proc Natl Acad Sci U S A (1999) 1.39
Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins (1995) 1.35
Synthetic transcripts of double-stranded Birnavirus genome are infectious. Proc Natl Acad Sci U S A (1996) 1.33
Structure of transfer RNAs: listing of 150 additional sequences. Prog Nucleic Acid Res Mol Biol (1983) 1.30
Foot-and-mouth disease virus immunogenic capsid protein VPT: N-terminal sequences and immunogenic peptides obtained by CNBr and tryptic cleavages. Intervirology (1979) 1.26
Mechanisms of receptor-mediated transmembrane communication. Cold Spring Harb Symp Quant Biol (1986) 1.22
Partial sequence analysis of cloned dengue virus type 2 genome. Gene (1986) 1.21
Generation of a mutant infectious bursal disease virus that does not cause bursal lesions. J Virol (1998) 1.14
A membrane-anchored cytoplasmic domain of the human insulin receptor mediates a constitutively elevated insulin-independent uptake of 2-deoxyglucose. Mol Endocrinol (1987) 1.11
Green fluorescent protein as a noninvasive stress probe in resting Escherichia coli cells. Appl Environ Microbiol (1999) 1.11
Cdc37 promotes the stability of protein kinases Cdc28 and Cak1. Mol Cell Biol (2000) 1.11
Purification and crystallization of human cyclin-dependent kinase 2. J Mol Biol (1993) 1.10
Molecular determinants of virulence, cell tropism, and pathogenic phenotype of infectious bursal disease virus. J Virol (2001) 1.10
Production of p60c-src by baculovirus expression and immunoaffinity purification. Methods Enzymol (1991) 1.09
Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop. Mol Cell Biol (2001) 1.09
Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants. J Gen Virol (1989) 1.06
Location of neutralizing epitopes defined by monoclonal antibodies generated against the outer capsid polypeptide, VP1, of foot-and-mouth disease virus A12. Virus Res (1984) 1.05
Heterologous transmembrane signaling by a human insulin receptor-v-ros hybrid in Chinese hamster ovary cells. Proc Natl Acad Sci U S A (1987) 1.05
Mapping surface structures of the human insulin receptor with monoclonal antibodies: localization of main immunogenic regions to the receptor kinase domain. Biochemistry (1986) 1.04
Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J Virol (1991) 1.04
Generation of infectious pancreatic necrosis virus from cloned cDNA. J Virol (1998) 1.03
A recombinant Eimeria protein inducing interferon-gamma production: comparison of different gene expression systems and immunization strategies for vaccination against coccidiosis. Avian Dis (2000) 1.03
Induction of apoptosis in vitro by the 17-kDa nonstructural protein of infectious bursal disease virus: possible role in viral pathogenesis. Virology (2001) 1.02
Foot-and-mouth disease virus: immunogenicity and structure of fragments derived from capsid protein VP and of virus containing cleaved VP. Vet Microbiol (1982) 1.01
Three-dimensional structure of human cyclin H, a positive regulator of the CDK-activating kinase. Nat Struct Biol (1996) 0.99
Immunogenicity of namogram to milligram quantities of inactivated foot-and-mouth disease virus. I. Relative virus-neutralizing potency of guinea pig sera. Appl Microbiol (1969) 0.98
Plate binding assay for monoclonal anti-receptor antibodies. Endocrinology (1985) 0.98
Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies. J Gen Virol (1986) 0.97
Butyrophilin is expressed in mammary epithelial cells from a single-sized messenger RNA as a type I membrane glycoprotein. J Biol Chem (1998) 0.97
Possible involvement of the double-stranded RNA-binding core protein sigmaA in the resistance of avian reovirus to interferon. J Virol (2000) 0.97
In vivo analysis of the stability and fitness of variants recovered from foot-and-mouth disease virus quasispecies. J Gen Virol (1998) 0.96
Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells. J Virol (1985) 0.96
The receptor for insulin-like growth factor II mediates an insulin-like response. EMBO J (1987) 0.96
Purification and characterization of the receptor for insulin-like growth factor I. Biochemistry (1986) 0.95
Linking functional domains of the human insulin receptor with the bacterial aspartate receptor. Proc Natl Acad Sci U S A (1986) 0.94
Identification of a monoclonal antibody which can distinguish between two distinct species of the type I receptor for insulin-like growth factor. Biochem Biophys Res Commun (1986) 0.93
Molecular cloning of the pheromone biosynthesis-activating neuropeptide in Helicoverpa zea. Proc Natl Acad Sci U S A (1992) 0.92
Naturally occurring-neutralizing monoclonal antibody escape variants define the epidemiology of infectious bursal disease viruses in the United States. Arch Virol (1992) 0.91
Molecular characterization of Sp serotype strains of infectious pancreatic necrosis virus exhibiting differences in virulence. Dis Aquat Organ (2004) 0.91
Antigenic comparison of different foot-and-mouth disease virus types using monoclonal antibodies defining multiple neutralizing epitopes on FMDV A5 subtypes. Virus Res (1989) 0.90
Use of in situ hybridization for the detection of foot-and-mouth disease virus in cell culture. J Vet Diagn Invest (1989) 0.90
Complete genome sequence of Newcastle disease virus mesogenic vaccine strain R2B from India. J Virol (2012) 0.90
Antigenic comparison of foot-and-mouth disease virus serotypes with monoclonal antibodies. Virus Res (1986) 0.89
Insulin and insulinlike growth factor receptors and responses in cultured human muscle cells. Am J Physiol (1986) 0.88
Characterization of anti-idiotypic antibodies generated against foot-and-mouth disease virus neutralizing monoclonal antibodies. Viral Immunol (1989) 0.88
Quantitation of the antigenicity and immunogenicity of purified foot-and-mouth disease virus vaccine for swine and steers. Appl Microbiol (1970) 0.86
Genetic variation of foot-and-mouth disease virus from field outbreaks to laboratory isolation. Virus Res (1994) 0.86
A novel transcutaneous plasmid-dimethylsulfoxide delivery technique for avian nucleic acid immunization. Vet Immunol Immunopathol (2002) 0.85
Protection of swine against foot-and-mouth disease with viral capsid proteins expressed in heterologous systems. Vaccine (1993) 0.85
Identification of virus neutralizing epitopes on naturally occurring variants of type A12 foot-and-mouth disease virus. Virus Res (1989) 0.85